Scientists propose CDK2 enzyme as new target for cancer therapy
An enzyme called cyclin-dependent kinase 2 (CDK2) regulates the cell cycle and may have the potential to drive therapeutic ...
Nature4d
FDA approves TROP2-targeted antibody–drug conjugate for breast cancer
The FDA in January approved ... receptor 2 (HER2)-negative breast cancer following endocrine-based therapy and chemotherapy. It is the second TROP2-targeted antibody–drug conjugate (ADC) to ...
Hartford Business2d
FDA approves CT drugmaker’s therapy for rare cancer tumors
Stamford-based SpringWorks Therapeutics, a commercial-stage biotech company developing treatments for rare diseases and ...
FiercePharma2d
Pfizer's blockbuster ADC Adcetris nabs FDA approval to treat large B-cell lymphoma
More than 13 years after its initial FDA approval, Pfizer’s blood cancer drug Adcetris has nabbed another regulatory green ...
University of California20h
Breast cancer treatment advances with light-activated ‘smart bomb’
It is a useful therapy with several drawbacks that limit its effectiveness, including prolonged light sensitivity, poor ...
Pfizer Receives Expanded FDA Approval for Cancer Treatment
The Food and Drug Administration expanded its approval of one of Pfizer's drugs, Adcetris, allowing it to be used as a treatment for certain types of lymphoma.
News Medical on MSN4d
Ariceum Therapeutics receives FDA’s Orphan Drug Designation for targeted radionuclide cancer treatment
Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announced that the U.S. Food ...
Targeted Oncology5d
The Targeted Pulse: The FDA Grants MB-105 ODD, and AI Helps Distinguish HER2 0 From 1+ in Breast Cancer
The FDA made strides in R/R T-cell lymphoma and breast cancer. An AI tool aids pathologists and other positive updates in gastric cancer and NSCLC.
Small-Cap OS Therapies Inks Commercial Manufacture Agreements For Lead Cancer Drug For Rare Type Of Bone Cancer
HER2, a HER2-targeted immunotherapy, with plans for FDA submission following promising Phase 2b data in osteosarcoma.
News Medical4d
Ariceum Therapeutics receives FDA’s Orphan Drug Designation for targeted radionuclide cancer treatment
SCLC is a deadly condition that represents a significant unmet medical need due to the limited number of treatment options available to patients with this aggressive form of cancer. Two-thirds of ...
SpringWorks Therapeutics Announces FDA Approval of GOMEKLIâ„¢ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
GOMEKLI is the first and only medicine approved for both adults and children with NF1-PN –– Approval based on positive data ...
Becker's Hospital Review4d
A spoonful of innovation: Karmanos pioneers at-home liver cancer treatment
TheraBionic is the only FDA-approved therapy indicated in liver cancer patients that fail first-line and second-line therapy, so that's really the place it takes right now in 2025. Patients can ...